Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02187744
Title A Study Of PF-05280014 Or Trastuzumab Plus Taxotere® And Carboplatin In HER2 Positive Breast Cancer In The Neoadjuvant Setting (REFLECTIONS B327-04)
Recruitment Completed
Phase Phase III
Variant Requirements No
Sponsors Pfizer

Her2-receptor positive breast cancer


Carboplatin + Docetaxel + Trastuzumab

Age Groups: adult
Covered Countries USA | ITA

No variant requirements are available.